Skip to main content
Market intelligence
DFTXSector not reported

Definium Therapeutics, Inc. insider activity

In the last 90 days, no corporate insiders reported open-market purchases.

SEC-reported filing activity is provided for research purposes and is not investment advice.

90-day C-suite buyers
0
90-day purchase value
$0.00
Corporate buyers
0
Latest transaction
Sep 25, 2026

Executive filings

Open-market transaction history

Purchase and sale summaries are ordered by the latest reported transaction date.

Open-market insider purchase and sale transactions
DateInsider nameRoleTypeSharesPriceTotal value
Sep 25, 2026Daniel KarlinChief Medical OfficerSale10,853$36.57$396,894
Sep 25, 2026Robert BarrowChief Executive OfficerSale31,550$36.57$1,153,784
Sep 25, 2026Matthew T. WileyChief Commercial OfficerSale3,097$36.57$113,257